The miRNA Profile of Inflammatory Colorectal Tumors Identify TGF-β as a Companion Target for Checkpoint Blockade Immunotherapy.

MSI PD-L1 checkpoint blockade immunotherapy mutation burden

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2021
Historique:
received: 06 08 2021
accepted: 13 09 2021
entrez: 1 11 2021
pubmed: 2 11 2021
medline: 2 11 2021
Statut: epublish

Résumé

Extrinsic factors such as expression of PD-L1 (programmed dealth-ligand 1) in the tumor microenvironment (TME) have been shown to correlate with responses to checkpoint blockade therapy. More recently two intrinsic factors related to tumor genetics, microsatellite instability (MSI), and tumor mutation burden (TMB), have been linked to high response rates to checkpoint blockade drugs. These response rates led to the first tissue-agnostic approval of any cancer therapy by the FDA for the treatment of metastatic, MSI-H tumors with anti-PD-1 immunotherapy. But there are still very few studies focusing on the association of miRNAs with immune therapy through checkpoint inhibitors. Our team sought to explore the biology of such tumors further and suggest potential companion therapeutics to current checkpoint inhibitors. Analysis by Pearson Correlation revealed 41 total miRNAs correlated with mutation burden, 62 miRNAs correlated with MSI, and 17 miRNAs correlated with PD-L1 expression. Three miRNAs were correlated with all three of these tumor features as well as M1 macrophage polarization. No miRNAs in any group were associated with overall survival. TGF-β was predicted to be influenced by these three miRNAs (

Identifiants

pubmed: 34722540
doi: 10.3389/fcell.2021.754507
pmc: PMC8551827
doi:

Types de publication

Journal Article

Langues

eng

Pagination

754507

Subventions

Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA188251
Pays : United States

Informations de copyright

Copyright © 2021 Bartlett, Gao, Schukking, Menor, Khadka, Fabbri, Fei and Deng.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
pubmed: 16461460
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
J Clin Endocrinol Metab. 2013 Aug;98(8):E1305-13
pubmed: 23796566
Cancer Res. 2009 Jul 1;69(13):5321-30
pubmed: 19531654
Curr Opin Genet Dev. 2018 Feb;48:128-133
pubmed: 29429825
Int J Cancer. 2020 Feb 15;146(4):1164-1173
pubmed: 31304978
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
BMC Cancer. 2016 Feb 16;16:108
pubmed: 26883911
Front Physiol. 2019 Jan 08;9:1879
pubmed: 30670982
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Nucleic Acids Res. 2018 Jan 4;46(D1):D239-D245
pubmed: 29156006
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
J Clin Lab Anal. 2019 Nov;33(9):e23004
pubmed: 31420913
Sci Rep. 2016 Dec 16;6:37446
pubmed: 27981970
Cell Biol Int. 2013 Jul;37(7):669-74
pubmed: 23483606
Clin Cancer Res. 2017 Jun 1;23(11):2891-2904
pubmed: 27903673
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Int J Mol Sci. 2017 Mar 15;18(3):
pubmed: 28294980
J Cancer. 2020 Jun 15;11(16):4899-4906
pubmed: 32626537
Oncogene. 2012 Apr 12;31(15):1910-22
pubmed: 21874046
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nature. 2005 Dec 1;438(7068):685-9
pubmed: 16258535
BMC Genomics. 2014;15 Suppl 11:S3
pubmed: 25559244
Int J Mol Sci. 2016 Oct 13;17(10):
pubmed: 27754357
J Cancer. 2016 Feb 05;7(5):490-9
pubmed: 26958084
Cell Signal. 2020 Feb;66:109470
pubmed: 31730895
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933
BMC Immunol. 2012 Jun 15;13:31
pubmed: 22703233
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9
pubmed: 16641092

Auteurs

Bjarne Bartlett (B)

Bioinformatics Core, Department of Quantitative Health Sciences, University of Hawaii, Honolulu, HI, United States.
Department of Molecular Biosciences and Bioengineering, University of Hawai'i at Mānoa, Honolulu, HI, United States.

Zitong Gao (Z)

Bioinformatics Core, Department of Quantitative Health Sciences, University of Hawaii, Honolulu, HI, United States.
Department of Molecular Biosciences and Bioengineering, University of Hawai'i at Mānoa, Honolulu, HI, United States.

Monique Schukking (M)

Department of Molecular Biosciences and Bioengineering, University of Hawai'i at Mānoa, Honolulu, HI, United States.
Cancer Biology Program, University of Hawai'i Cancer Center, Honolulu, HI, United States.

Mark Menor (M)

Bioinformatics Core, Department of Quantitative Health Sciences, University of Hawaii, Honolulu, HI, United States.

Vedbar S Khadka (VS)

Bioinformatics Core, Department of Quantitative Health Sciences, University of Hawaii, Honolulu, HI, United States.

Muller Fabbri (M)

Cancer Biology Program, University of Hawai'i Cancer Center, Honolulu, HI, United States.

Peiwen Fei (P)

Cancer Biology Program, University of Hawai'i Cancer Center, Honolulu, HI, United States.

Youping Deng (Y)

Bioinformatics Core, Department of Quantitative Health Sciences, University of Hawaii, Honolulu, HI, United States.
Department of Molecular Biosciences and Bioengineering, University of Hawai'i at Mānoa, Honolulu, HI, United States.

Classifications MeSH